Strategic exits Gilgamesh Pharma recently completed a $60M Series A and has already sold a asset (bretisilocin) to AbbVie for up to $1.2B, signaling a readiness to monetize assets and attract big pharma collaboration. This suggests sales opportunities in licensing, partnerships, and future asset divestitures with large pharmaceutical buyers.

Neuropsychiatric focus The company concentrates on rapid-acting, durable therapies addressing fundamental drivers of psychiatric illness, with programs like GM-3009 for PTSD and ibogaine derivatives for MDD and SUD. This positions them to be a potential partner or customer for specialized CNS delivery, companion diagnostics, and CNS-focused contract research organizations.

Early-stage upside With early-stage clinical testing for GM-3009 and a cardiac-safety focus for psychedelic derivatives, Gilgamesh represents a partner for early-stage clinical services, translational research collaborations, and technology licensing opportunities to accelerate safety and efficacy profiling.

Funding momentum A $60M Series A alongside a $149M funding framework indicates strong investor appetite and ongoing capital to scale operations, making them a viable target for collaboration on co-development, joint ventures, or strategic advisory engagements to maximize portfolio value.

Regulatory readiness Appointment of a VP Regulatory Affairs and US-centric regulatory strategy signals a focus on navigating approvals efficiently, offering opportunities to engage in regulatory consulting, submissions support, and market access partnerships to accelerate product timelines.